Published articles & abstracts

Journal of Cancer Therapy, 2019, 10, 580-590.

Published: 24 July 2019

Document: JCT_2019072315145979

Authors: Maria Papadimitriou, Eleana Hatzidaki, Ioannis Papasotiriou

Read article

ESHO_2019_Presentation.

Published: 1 May 2019

Document: ESHO_2019_Presentation

Authors: Panagiotis Apostolou, Dimitrios-Athanasios Ntanovasilis, Ioannis Papasotiriou

Read article

Abstract ESHO Annual-2019.

Published: 1 May 2019

Document: Abstract ESHO Annual-2019

Authors: Apostolou, Dimitrios-Athanasios Ntanovasilis, Ioannis Papasotiriou

Read article

Identification of new targets and biomarkers in lung cancer.

Published: 1 June 2019

Link: https://abstracts.asco.org/239/AbstView_239_263135.html

Authors: Panagiotis Apostolou, Dimitrios-Athanasios Ntanovasilis, Ioannis Papasotiriou

Read article

Gene expression profiling as a potential predictor between normal and cancer samples in gastrointestinal carcinoma.

Published: 21 May 2019

Document: Oncotarget

Authors: Panagiotis Apostolou, Aggelos C. Iliopoulos, Panagiotis Parsonidis and Ioannis Papasotiriou

Read article

Novel small molecule decreases cell proliferation, migration, clone formation, and gene expression through ERK inhibition in MCF-7 and MDA-MB-231 breast cancer cell lines.

Published: 6 February 2019

Link: https://www.ncbi.nlm.nih.gov/pubmed/30741723

Authors: Hatzidaki E, Parsonidis P, Apostolou P, Daikopoulou V, Papasotiriou I.

Read article

Folic Acid-Functionalized Gold Nanorods for Controlled Paclitaxel Delivery: In Vitro Evaluation and Cell Studies.

Published: 1 December 2018

Link: https://www.ncbi.nlm.nih.gov/pubmed/30560417

Authors: Papaioannou L, Angelopoulou A, Hatziantoniou S, Papadimitriou M, Apostolou P, Papasotiriou I, Avgoustakis K.

Read article

The use of serum extracellular vesicles for novel small molecule inhibitor cell delivery.

Published: 26 November 2018

Link: https://www.ncbi.nlm.nih.gov/pubmed/30489291

Authors: Hatzidaki E, Vlachou I, Elka A, Georgiou E, Papadimitriou M, Iliopoulos A, Papasotiriou I.

Read article

Risk prediction of metastasis through study of circulating tumor cells.

Published: 19 October 2018

Document: Risk prediction of metastasis through study of circulating tumor cells

Authors: Apostolou P., Papasotiriou I.

Read article

Retrotransposons in circulating free DNA from cancer patients.

Published: 28 September 2018

Document: Poster DGHO Jahrestagung 2018

Authors: Apostolou P., Parsonidis P., Papasotiriou I.

Read article

CD163 detection in breast cancer patients’ peripheral blood. A possible marker?

Published: 1 September 2018

Document: ESCAA Poster Sept 2018

Authors: Ntanovasilis D.A., Papasotiriou I.

Read article

Quantitative Nuclear Magnetic Resonance for the determination of Genistein in capsules.

Published: 1 July 2018

Document: poster-ioanna vlachou euromar 2018

Authors: Vlachou I, Papasotiriou I.

Read article

Published articles & abstracts

Journal of Cancer Therapy, 2019, 10, 580-590.

ESHO_2019_Presentation.

Abstract ESHO Annual-2019.

Identification of new targets and biomarkers in lung cancer.

Gene expression profiling as a potential predictor between normal and cancer samples in gastrointestinal carcinoma.

Novel small molecule decreases cell proliferation, migration, clone formation, and gene expression through ERK inhibition in MCF-7 and MDA-MB-231 breast cancer cell lines.

Folic Acid-Functionalized Gold Nanorods for Controlled Paclitaxel Delivery: In Vitro Evaluation and Cell Studies.

The use of serum extracellular vesicles for novel small molecule inhibitor cell delivery.

Risk prediction of metastasis through study of circulating tumor cells.

Retrotransposons in circulating free DNA from cancer patients.

CD163 detection in breast cancer patients’ peripheral blood. A possible marker?

Quantitative Nuclear Magnetic Resonance for the determination of Genistein in capsules.

Need help?

Will you send me the results directly?

Do I need to go through my GP to get a test?

Can RGCC test for BRAF drugs?

Can the Oncotrace test differentiate between benign and malignant tumour cells?

I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?

Global Presence